News
Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026
Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026
Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial
Oncoinvent ASA: Registration of reverse share split
Oncoinvent ASA: Ex. reverse share split and change of ISIN today
Oncoinvent ASA – New share capital registered
Oncoinvent ASA: Key information relating to the reverse share split and change of ISIN
Oncoinvent ASA: Grant of share options to new CFO
Oncoinvent ASA: Minutes from Extraordinary General Meeting
